Comparison of reported features in animal models of SS with the human disease
| Strain | Clinical feature | Histological* | Associated features | Age of detection | Ratios female:male | Reference | |||
|---|---|---|---|---|---|---|---|---|---|
| KCS | Xerostomia | Serological markers | Lachrymal | Salivary | |||||
| NOD, non-obese diabetic; NOD.B10.H2b, substrain of NOD which lacks insulitis; MRL/Lpr, MRL+, MRL+/lpr, different mouse substrains developed from crosses involving a number of standard inbred strains (AKR/J, C57BL/6J, C3H/Di, and LG/J); a mutation; lpr (lymphoproliferation) was found in the 12th generation of brother-sister matings. NFS/sld, NSF mice carrying mutant sld gene, thymectomised three days after birth; IDDM, insulin dependent diabetes mellitus; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis, SCID, severe combined immunodeficiency; ND, not done; Ab, antibody; KCS, keratoconjunctivitis sicca. | |||||||||
| *Cellular lymphocytic infiltrate and tissue damage. | |||||||||
| Human | + | + | Hypergamma-globulinaemia, ANA, SSA/SSB, RF | + | + | Secondary: SLE, RA, scleroderma, glomerulonephritis | >50 Years | 9:1 | 1, 13 |
| NOD | + | + | Anti-M3, SSA/SSB | + | + | IDDM | 8 Weeks | F>M | 89, 90 |
| NOD.B10.H2b | − | − | ND | + | + | ND | 8–12 Weeks | ND | 93 |
| NOD-SCID | − | − | ND | − | − | SCID, IDDM, glomerulonephritis | 8–10 Weeks | ND | 94 |
| MRL/lpr | − | − | SSA/SSB | + | + | Arthritis, vasculitis, lymphadenopathy as above, etc | ? | F>M | 79, 84 |
| MRL+/lpr | − | − | SSA/SSB | ND | + | Fulminant, chronic | ? | F>M | 81 |
| MRL/+ | − | − | SSA/SSB | + | + | Glomerulonephritis, less fulminant, lupus | ? | F>M | 81 |
| NZB | + | − | − | + | + | Glomerulonephritis, lupus | 16 Weeks | 1:1 | 77 |
| NZB/NZW | + | − | − | + | + | Glomerulonephritis, more severe | 16 Weeks | 1:1 | 77 |
| NFS/sld | − | − | Ab against ssDNA, anti-salivary duct Ab | + | + | ND | 4–8 Weeks | Lesions F>M | 86, 87 |